- Home
- DVS vs VNDA Comparison
DVS vs VNDA Comparison
Compare DVS & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- VNDA
- Stock Information
- Founded
- DVS 2011
- VNDA 2002
- Country
- DVS Canada
- VNDA United States
- Employees
- DVS N/A
- VNDA N/A
- Industry
- DVS
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- VNDA Health Care
- Exchange
- DVS Nasdaq
- VNDA Nasdaq
- Market Cap
- DVS 210.3M
- VNDA 237.9M
- IPO Year
- DVS N/A
- VNDA 2006
- Fundamental
- Price
- DVS $2.93
- VNDA $4.34
- Analyst Decision
- DVS
- VNDA Strong Buy
- Analyst Count
- DVS 0
- VNDA 3
- Target Price
- DVS N/A
- VNDA $15.33
- AVG Volume (30 Days)
- DVS 236.2K
- VNDA 519.0K
- Earning Date
- DVS 05-14-2025
- VNDA 05-07-2025
- Dividend Yield
- DVS N/A
- VNDA N/A
- EPS Growth
- DVS N/A
- VNDA N/A
- EPS
- DVS N/A
- VNDA N/A
- Revenue
- DVS N/A
- VNDA $201,351,000.00
- Revenue This Year
- DVS N/A
- VNDA $16.86
- Revenue Next Year
- DVS N/A
- VNDA $39.78
- P/E Ratio
- DVS N/A
- VNDA N/A
- Revenue Growth
- DVS N/A
- VNDA 13.37
- 52 Week Low
- DVS $2.48
- VNDA $3.81
- 52 Week High
- DVS $3.00
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- DVS N/A
- VNDA 51.79
- Support Level
- DVS N/A
- VNDA $4.17
- Resistance Level
- DVS N/A
- VNDA $4.41
- Average True Range (ATR)
- DVS 0.00
- VNDA 0.16
- MACD
- DVS 0.00
- VNDA 0.03
- Stochastic Oscillator
- DVS 0.00
- VNDA 73.61
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.